Clinical trial design issues in the era of targeted therapies

被引：6

作者：

Schiller, JH ^{[1
]}

机构：

[1] Univ Wisconsin, Sch Med, Madison, WI 53792 USA

来源：

CLINICAL CANCER RESEARCH | 2004年 / 10卷 / 12期

关键词：

D O I：

10.1158/1078-0432.CCR-040008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although our lack of effective therapies mandates the development of new, molecularly targeted therapies, a number of issues in the design of clinical trials and their end points remain to be considered.

引用

页码：4281S / 4282S

页数：2

共 21 条

[1]

Arteaga CL, 2003, CLIN CANCER RES, V9, P1579

[2] Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing [J].

Baselga, J .

ANNALS OF ONCOLOGY, 2002, 13 (01) :8-9

[3] EARLY STOPPING RULES - CLINICAL PERSPECTIVES AND ETHICAL CONSIDERATIONS [J].

BAUM, M ;

HOUGHTON, J ;

ABRAMS, K .

STATISTICS IN MEDICINE, 1994, 13 (13-14) :1459-1469

[4]

Freidlin B, 2003, CLIN CANCER RES, V9, P917

[5] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[6] Pleural mesothelioma: combined modality treatments [J].

Giaccone, G .

ANNALS OF ONCOLOGY, 2002, 13 :217-225

[7]

Herndon JE, 1998, CONTROL CLIN TRIALS, V19, P440

[8] Seamlessly expanding a randomized phase II trial to phase III [J].

Inoue, LYT ;

Thall, PF ;

Berry, DA .

BIOMETRICS, 2002, 58 (04) :823-831

[9]

JOHNSON DH, 2002, ANN ONCOL, V13, P127

[10]

Kris M.G., 2002, P AM SOC CLIN ONCOL, V21, p292a

← 1 2 3 →